Methods and reagents for the treatment of metabolic disorders
AssigneeCombinatoRx, Incorporated
InventorsMargaret S. Lee, Grant R. Zimmermann, Alyce L. Finelli, Daniel Grau, Curtis Keith, M. James Nichols
Life of this patent
Estimating the term…
Abstract
The invention features compositions, methods, and kits for the treatment of metabolic disorders such as diabetes and obesity.
Claims6
A composition consisting of active and inert ingredients, wherein the sole active ingredients are:
- (a) a fibrate selected from the group consisting of bezafibrate, binifibrate, ciprofibrate, clinofibrate, clofibrate, etofibrate, fenofibrate, and gemfibrozil;
- and
- (b) diflunisal, a diflunisal analog, cinnamic acid, or a cinnamic acid analog, wherein said diflunisal analog has the structure of formula (III):
- wherein each X is, independently, a halogen atom;
- R1 is hydroxy, phenoxy, di(C1-C4)alkylamino, di(C1-C4)alkylamino, or (C1-C4)alkoxy;
- R2 is hydrogen or (C1-C4)alkanoyl;
- and R3 is hydrogen or methyl;
- wherein said cinammic acid analog has the structure of formula (II):
- wherein R1 and R2 are each, independently, a hydrogen atom or a C1-4 alkyl group;
- R3 and R4 each represent a hydrogen atom or may be combined together to form an additional chemical bond;
- n is zero or an integer from 1 to 3;
- each X is, independently, a hydroxyl group, a halogen atom, a straight or branched chain saturated or unsaturated C1-4 alkyl group, a straight or branched chain saturated or unsaturated C1-4 alkoxy group, a C1-4 acyloxy group, or a C3-6 cycloalkyl group;
- when n is 2 or 3 and two X's are commonly C1-4 alkyl or C1-4 alkoxy, both X's may be combined together to form a ring.
A composition consisting of active and inactive ingredients, wherein the sole active ingredients are bezafibrate and diflunisal.
A composition consisting of active and inactive ingredients, wherein the sole active ingredients are bezafibrate and cinnamic acid.
A composition consisting of active and inactive ingredients, wherein the sole active ingredients are:
- (a) bezafibrate or a bezafibrate analog having a structure of formula (I):
- wherein R1 and R2 are each, independently, hydrogen, halogen, C1-4 alkyl, or C1-4 alkoxy;
- R3 and R4 are each, independently, hydrogen or C1-4 alkyl;
- n is 1, 2, or 3;
- and Z is hydroxyl or C1-4 alkyl;
- and
- (b) diflunisal, a diflunisal analog, cinnamic acid, or a cinnamic acid analog;
- wherein said diflunisal analog has the structure of formula (III):
- wherein each X is, independently, a halogen atom;
- R1 is hydroxy, phenoxy, di(C1-C4)alkylamino, di(C1-C4)alkylamino, or (C1-C4)alkoxy;
- R2 is hydrogen or (C1-C4)alkanoyl;
- and R3 is hydrogen or methyl;
- wherein said cinnamic acid analog has the structure of formula (II):
- wherein R1 and R2 are each, independently, a hydrogen atom or a C1-4 alkyl group;
- R3 and R4 each represent a hydrogen atom or may be combined together to form an additional chemical bond;
- n is zero or an integer from 1 to 3;
- each X is, independently, a hydroxyl group, a halogen atom, a straight or branched chain saturated or unsaturated C1-4 alkyl group, a straight or branched chain saturated or unsaturated C1-4 alkoxy group, a C1-4 acyloxy group, or a C3-6 cycloalkyl group;
- when n is 2 or 3 and two X's are commonly C1-4 alkyl or C1-4 alkoxy, both X's may be combined together to form a ring.
Dependencies are inferred from the claim text.